Necrotizing enterocolitis following diazoxide therapy for persistent neonatal hypoglycemia

Area of Science:

• Neonatology
• Pediatric Endocrinology
• Clinical Pharmacology

Background:

• Neonatal hypoglycemia is a common clinical challenge, especially when unresponsive to standard dextrose therapy.
• Diazoxide is a medication used for refractory hypoglycemia, but it carries potential side effects like fluid retention and heart failure.
• Beckwith-Wiedemann Syndrome is associated with persistent hypoglycemia, requiring careful management.

Purpose of the Study:

• To report a case of persistent neonatal hypoglycemia in a patient with Beckwith-Wiedemann Syndrome.
• To describe the management of this condition using escalating doses of diazoxide.
• To highlight the potential complications and therapeutic considerations when using diazoxide in this context.

Main Methods:

• A case report of a neonate with Beckwith-Wiedemann Syndrome and persistent hypoglycemia was reviewed.
• The patient received escalating doses of diazoxide for treatment of hypoglycemia.
• Clinical monitoring for efficacy and side effects, including necrotizing enterocolitis, was performed.

Main Results:

• The patient with Beckwith-Wiedemann Syndrome experienced persistent neonatal hypoglycemia refractory to dextrose.
• Escalating doses of diazoxide were administered to manage the hypoglycemia.
• The case involved the co-occurrence of necrotizing enterocolitis, requiring careful consideration of treatment strategies.

Conclusions:

• Diazoxide can be a viable option for managing persistent neonatal hypoglycemia in complex cases like Beckwith-Wiedemann Syndrome.
• Close monitoring for side effects, such as fluid retention and gastrointestinal issues like necrotizing enterocolitis, is crucial.
• Individualized treatment titration is essential for optimizing outcomes in refractory neonatal hypoglycemia.